lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts. Sortable columns (indexed): client_name, issue_code, filing_year, filing_uuid. Sorting on any other column returns HTTP 400 (2026-09-04, #697) — use ?sql= with your own ORDER BY if you need it.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

18 rows where filing_uuid = "fe475758-bcd3-4425-91d4-f201dfa8dcc5" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

issue_code 6

filing_year 1

filing_period 1

id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities is_no_activity is_termination received_date
3343658 AMERICAN SOCIETY OF ADDICTION MEDICINE fe475758-bcd3-4425-91d4-f201dfa8dcc5 Q1 AMERICAN SOCIETY OF ADDICTION MEDICINE 401104864 AMERICAN SOCIETY OF ADDICTION MEDICINE 2025 first_quarter ALC Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in … Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) 0 0 2025-04-18T06:45:22-04:00
3343659 AMERICAN SOCIETY OF ADDICTION MEDICINE fe475758-bcd3-4425-91d4-f201dfa8dcc5 Q1 AMERICAN SOCIETY OF ADDICTION MEDICINE 401104864 AMERICAN SOCIETY OF ADDICTION MEDICINE 2025 first_quarter HCR Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in … Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) 0 0 2025-04-18T06:45:22-04:00
3343660 AMERICAN SOCIETY OF ADDICTION MEDICINE fe475758-bcd3-4425-91d4-f201dfa8dcc5 Q1 AMERICAN SOCIETY OF ADDICTION MEDICINE 401104864 AMERICAN SOCIETY OF ADDICTION MEDICINE 2025 first_quarter MED Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in … Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) 0 0 2025-04-18T06:45:22-04:00
3343661 AMERICAN SOCIETY OF ADDICTION MEDICINE fe475758-bcd3-4425-91d4-f201dfa8dcc5 Q1 AMERICAN SOCIETY OF ADDICTION MEDICINE 401104864 AMERICAN SOCIETY OF ADDICTION MEDICINE 2025 first_quarter MMM Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in … Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) 0 0 2025-04-18T06:45:22-04:00
3343662 AMERICAN SOCIETY OF ADDICTION MEDICINE fe475758-bcd3-4425-91d4-f201dfa8dcc5 Q1 AMERICAN SOCIETY OF ADDICTION MEDICINE 401104864 AMERICAN SOCIETY OF ADDICTION MEDICINE 2025 first_quarter BUD Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in … Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) 0 0 2025-04-18T06:45:22-04:00
3343663 AMERICAN SOCIETY OF ADDICTION MEDICINE fe475758-bcd3-4425-91d4-f201dfa8dcc5 Q1 AMERICAN SOCIETY OF ADDICTION MEDICINE 401104864 AMERICAN SOCIETY OF ADDICTION MEDICINE 2025 first_quarter INS Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in … Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) 0 0 2025-04-18T06:45:22-04:00
3544520 AMERICAN SOCIETY OF ADDICTION MEDICINE fe475758-bcd3-4425-91d4-f201dfa8dcc5 Q1 AMERICAN SOCIETY OF ADDICTION MEDICINE 401104864 AMERICAN SOCIETY OF ADDICTION MEDICINE 2025 first_quarter ALC Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in … Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) 0 0 2025-04-18T06:45:22-04:00
3544521 AMERICAN SOCIETY OF ADDICTION MEDICINE fe475758-bcd3-4425-91d4-f201dfa8dcc5 Q1 AMERICAN SOCIETY OF ADDICTION MEDICINE 401104864 AMERICAN SOCIETY OF ADDICTION MEDICINE 2025 first_quarter HCR Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in … Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) 0 0 2025-04-18T06:45:22-04:00
3544522 AMERICAN SOCIETY OF ADDICTION MEDICINE fe475758-bcd3-4425-91d4-f201dfa8dcc5 Q1 AMERICAN SOCIETY OF ADDICTION MEDICINE 401104864 AMERICAN SOCIETY OF ADDICTION MEDICINE 2025 first_quarter MED Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in … Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) 0 0 2025-04-18T06:45:22-04:00
3544523 AMERICAN SOCIETY OF ADDICTION MEDICINE fe475758-bcd3-4425-91d4-f201dfa8dcc5 Q1 AMERICAN SOCIETY OF ADDICTION MEDICINE 401104864 AMERICAN SOCIETY OF ADDICTION MEDICINE 2025 first_quarter MMM Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in … Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) 0 0 2025-04-18T06:45:22-04:00
3544524 AMERICAN SOCIETY OF ADDICTION MEDICINE fe475758-bcd3-4425-91d4-f201dfa8dcc5 Q1 AMERICAN SOCIETY OF ADDICTION MEDICINE 401104864 AMERICAN SOCIETY OF ADDICTION MEDICINE 2025 first_quarter BUD Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in … Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) 0 0 2025-04-18T06:45:22-04:00
3544525 AMERICAN SOCIETY OF ADDICTION MEDICINE fe475758-bcd3-4425-91d4-f201dfa8dcc5 Q1 AMERICAN SOCIETY OF ADDICTION MEDICINE 401104864 AMERICAN SOCIETY OF ADDICTION MEDICINE 2025 first_quarter INS Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in … Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) 0 0 2025-04-18T06:45:22-04:00
3615725 AMERICAN SOCIETY OF ADDICTION MEDICINE fe475758-bcd3-4425-91d4-f201dfa8dcc5 Q1 AMERICAN SOCIETY OF ADDICTION MEDICINE 401104864 AMERICAN SOCIETY OF ADDICTION MEDICINE 2025 first_quarter ALC Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in … Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) 0 0 2025-04-18T06:45:22-04:00
3615726 AMERICAN SOCIETY OF ADDICTION MEDICINE fe475758-bcd3-4425-91d4-f201dfa8dcc5 Q1 AMERICAN SOCIETY OF ADDICTION MEDICINE 401104864 AMERICAN SOCIETY OF ADDICTION MEDICINE 2025 first_quarter HCR Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in … Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) 0 0 2025-04-18T06:45:22-04:00
3615727 AMERICAN SOCIETY OF ADDICTION MEDICINE fe475758-bcd3-4425-91d4-f201dfa8dcc5 Q1 AMERICAN SOCIETY OF ADDICTION MEDICINE 401104864 AMERICAN SOCIETY OF ADDICTION MEDICINE 2025 first_quarter MED Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in … Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) 0 0 2025-04-18T06:45:22-04:00
3615728 AMERICAN SOCIETY OF ADDICTION MEDICINE fe475758-bcd3-4425-91d4-f201dfa8dcc5 Q1 AMERICAN SOCIETY OF ADDICTION MEDICINE 401104864 AMERICAN SOCIETY OF ADDICTION MEDICINE 2025 first_quarter MMM Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in … Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) 0 0 2025-04-18T06:45:22-04:00
3615729 AMERICAN SOCIETY OF ADDICTION MEDICINE fe475758-bcd3-4425-91d4-f201dfa8dcc5 Q1 AMERICAN SOCIETY OF ADDICTION MEDICINE 401104864 AMERICAN SOCIETY OF ADDICTION MEDICINE 2025 first_quarter BUD Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in … Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) 0 0 2025-04-18T06:45:22-04:00
3615730 AMERICAN SOCIETY OF ADDICTION MEDICINE fe475758-bcd3-4425-91d4-f201dfa8dcc5 Q1 AMERICAN SOCIETY OF ADDICTION MEDICINE 401104864 AMERICAN SOCIETY OF ADDICTION MEDICINE 2025 first_quarter INS Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in … Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) 0 0 2025-04-18T06:45:22-04:00

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options: 

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);